Forecast Ledgerinterventional psychiatry and psychedelic medicineQuoted, dated predictions scored against public outcomes under one written method. Every score links to the words, the rule and the evidence.

Company and market outcomes

Rules 1.1.0 · as of 14 Sep 2026

Acquisitions, financings, listings, bankruptcies, layoffs, launches, revenue and share-price thresholds for companies in the field.

Leaderboard

No forecaster has 5 resolved events yet.

score95% rangeprovisional (under 30 events)resolved events toward the 5 a score needsreference rowcoin flip 0.25
COIN FLIPANGERMAYER2of 5DOBLIN0of 5MUIR2of 500.10.20.30.40.5← BETTERBRIER
How to read
Persons are ranked only when both have 5 or more resolvedA cluster with at least one scored item. Only resolved clusters count toward n. Method › events, share a coverage tierHow completely a person's claims were collected: A complete archive, B archive plus search, C search-built. Ranks are shown only inside one tier. Method ›, and their intervalsThe 2.5 and 97.5 percentiles of a statistic over many resamples of the clusters with replacement, drawn with a seeded generator so every run gives the same interval. It shows how much the number could move if the events were redrawn. Method › do not overlap; otherwise rows are alphabetical. The evidence tierHow much resolved evidence a person has: T0 fewer than 10 clusters (counts only), T1 10 to 29 (provisional), T2 30 or more (full). Method › sets whether a row shows a score or a count. Comparators are ad hoc collections (tier C): they get a score at the same minimum, but a search-built corpus under-counts claims, so they are never ranked against the full archive. The reference rowsA leaderboard row that is not a person: the base rate or the market, scored with its own probability on the same clusters. Shows what a rule of thumb would have scored. Method › are scored on the same events; the coin flipThe constant 0.25, the Brier score of saying 0.50 on every item. Drawn as a reference line; not a row on the leaderboard. Method › is the score of saying fifty-fifty every time.

Company and market outcomes · 4 events

Status

3 of 4 resolved claims came true.

TRUETRUE3FALSEFALSE1KNOWN TRUEKNOWN TRUE2PENDINGPENDING9VOIDVOID116ITEMS1 TICK = 1 ITEM

Company and market outcomes · 16 items

Claims and events

16 claims against 53 events in the field.

saiddueevent
6 Mar 2023 · atai Life Sciences: atai lays off about 30% of staff and reviews its pipeline two months after the P7 Mar 2023 · Synthesis Institute: Synthesis Institute, a psilocybin retreat operator and Oregon's largest facilita16 Mar 2023 · Ketamine Wellness Centers (Delic Holdings): Ketamine Wellness Centers, a Delic Holdings subsidiary, abruptly shuts all of it22 Mar 2023 · Field Trip Health & Wellness: Field Trip Health & Wellness obtains CCAA creditor protection from the Ontario S5 Jul 2023 · Wesana Health: Wesana Health closes the sale of its SANA-013 assets, completing its exit from t16 Aug 2023 · Compass Pathways: Compass Pathways raises $285M in a private placement to fund the COMP360 phase 315 Sep 2023 · Neumora Therapeutics: Neumora completes a $250M IPO to fund late-stage navacaprant depression trials.26 Oct 2023 · Nue Life Health: Venture studio Beckley Waves acquires ketamine telehealth company Nue Life after22 Dec 2023 · Bristol Myers Squibb / Karuna Therapeutics: Bristol Myers Squibb agrees to acquire Karuna Therapeutics, adding KarXT ahead o4 Jan 2024 · atai Life Sciences / Beckley Psytech: atai makes a $50M strategic investment in Beckley Psytech, taking a minority sta5 Jan 2024 · Lykos Therapeutics (ex-MAPS PBC): MAPS PBC rebrands as Lykos Therapeutics and raises a $100M Series A ahead of its18 Mar 2024 · Cybin: Cybin closes an oversubscribed $150M private placement to fund CYB003 phase 3 anCYBIN: CYBIN CLOSES AN OVERSUBSCRIBED $150M PRIVATE PLACEMENT TO FUND CYB003 PHASE 3 AN13 Jun 2024 · Done Global: Done Global CEO Ruthia He and clinical president David Brody are arrested on fed12 Aug 2024 · Neuronetics / Greenbrook TMS: Neuronetics agrees an all-stock merger with Greenbrook TMS, the largest US TMS c13 Aug 2024 · MindMed: MindMed closes a $75M public offering, bringing 2024 gross equity raises to abou15 Aug 2024 · Lykos Therapeutics: Lykos cuts about 75% of its roughly 100 staff after the CRL and retractions; fou5 Sep 2024 · Lykos Therapeutics: Lykos CEO Amy Emerson steps down; COO Michael Mullette becomes interim CEO and D31 Oct 2024 · Compass Pathways: Compass delays COMP005 topline to Q2 2025 and COMP006 data to after the 26-week 15 Nov 2024 · Numinus Wellness / Stella: Numinus agrees to sell its five Utah wellness clinics to Stella MSO and pivots t9 Dec 2024 · Neuronetics / Greenbrook TMS: Neuronetics completes the Greenbrook TMS merger, becoming a vertically integrate17 Dec 2024 · Numinus Wellness / Stella: Numinus closes the sale of its US clinics to Stella and launches a data-sharing 10 Jan 2025 · Lykos Therapeutics / Antonio Gracias: Billionaire investor Antonio Gracias moves to take control of Lykos with about $13 Jan 2025 · Johnson & Johnson / Intra-Cellular Therapies: J&J agrees to acquire Intra-Cellular Therapies (Caplyta) in its largest neurosci15 Jan 2025 · Lykos Therapeutics: Five Lykos board directors depart as the company seeks new funding after the FDA22 Jan 2025 · Johnson & Johnson (Spravato): J&J Q4 2024 results show Spravato crossed $1B in annual sales for the first time30 May 2025 · Lykos Therapeutics: Lykos completes the first close of a Series B co-led by the Gracias Family Found2 Jun 2025 · atai Life Sciences / Beckley Psytech: atai agrees an all-share combination with Beckley Psytech, contingent on BPL-00316 Jun 2025 · Supernus Pharmaceuticals / Sage Therapeutics: Supernus agrees to acquire Sage Therapeutics (Zurzuvae) after Sage rebuffed Biog23 Jun 2025 · Compass Pathways: Compass shares fall sharply as investors judge the 3.6-point COMP005 effect size30 Jun 2025 · Cybin: Cybin announces a financing of up to $500M in convertible debentures to fund its20 Aug 2025 · Lykos Therapeutics: Lykos names former Point72 capital markets head Nick McEntire as president under28 Aug 2025 · Lykos Therapeutics / Resilient Pharmaceuticals: Lykos Therapeutics rebrands as Resilient Pharmaceuticals following the Gracias-l22 Oct 2025 · Mindbloom: A wrongful-death lawsuit is filed against at-home ketamine provider Mindbloom ov31 Oct 2025 · MindMed: MindMed closes an upsized underwritten public offering after positive phase 3 pl5 Nov 2025 · AtaiBeckley: atai and Beckley Psytech complete their combination to form AtaiBeckley; a $150M19 Nov 2025 · Done Global: A federal jury convicts Done founder Ruthia He and clinical president David Brod17 Dec 2025 · Done Global: A federal grand jury indicts Done Global itself over the alleged $100M Adderall 5 Jan 2026 · Cybin / Helus Pharma: Cybin rebrands as Helus Pharma and moves its US listing to Nasdaq under ticker H12 Jan 2026 · MindMed / Definium Therapeutics: MindMed rebrands as Definium Therapeutics (Nasdaq: DFTX from Jan 15) and guides 21 Jan 2026 · Johnson & Johnson (Spravato): J&J full-year 2025 results show Spravato sales of about $1.7B, with Q4 2025 up 618 Feb 2026 · Compass Pathways: Compass prices a $150M public offering the day after COMP006 topline; with warra1 Mar 2026 · Alto Neuroscience: Alto closes a $120M private placement led by Commodore Capital at $20 per share,17 Mar 2026 · Neuronetics: Neuronetics appoints Dan Reuvers as CEO as 2025 revenue nearly doubles after the7 Apr 2026 · Neuronetics: Neuronetics' top shareholder says the company has 'chronically underperformed' a29 Apr 2026 · GH Research: GH Research prices a $117.5M underwritten offering at $18 per share to fund the 13 May 2026 · Compass Pathways: Compass Q1 2026 update: rolling NDA sections already submitted, final submission25 Jun 2026 · Definium Therapeutics: Definium closes an upsized $805M public offering at $34 per share three days aft25 Jun 2026 · Helus Pharma: Helus completes a $50M underwritten offering, lifting cash to about $207M ahead 8 Jul 2026 · Done Global: Done founder Ruthia He is sentenced to 72 months in prison and fined $90M for th15 Jul 2026 · Johnson & Johnson (Spravato): J&J Q2 2026 results show Spravato sales of $584M, up 25% quarter over quarter an16 Jul 2026 · Eli Lilly / AtaiBeckley: Lilly agrees to acquire AtaiBeckley for $6.75 per share cash plus a CVR of up to3 Aug 2026 · Helus Pharma: Helus Pharma appoints Michael Halstead as chief executive officer ahead of its p11 Sep 2026 · Eli Lilly / AtaiBeckley: Eli Lilly completes its acquisition of AtaiBeckley, taking BPL-003 and VLS-01 inSAINT NEUROMODULA…SAINT neuromodulation system becomes commercially available in the US · stated 8 Sep 2022SAINT neuromodulation system becomes commercially available in the US · restated 8 Sep 2022 · p 90%SAINT neuromodulation system becomes commercially available in the US · hit 30 Apr 2024ATAI LIFE SCIENCE…atai Life Sciences market capitalization at or above US$10 billion · stated 16 Nov 2022atai Life Sciences market capitalization at or above US$10 billion · restated 16 Nov 2022 · p 50%BETTERHELP OR TEL…BetterHelp or Teladoc Health ceases operations · stated 12 Mar 2023BetterHelp or Teladoc Health ceases operations · restated 12 Mar 2023 · p 50%BetterHelp or Teladoc Health ceases operations · miss 12 Mar 2025SPRAVATO ANNUAL S…Spravato annual sales at or above US$1 billion · stated 24 Jun 2024Spravato annual sales at or above US$1 billion · restated 24 Jun 2024 · p 70%Spravato annual sales at or above US$1 billion · hit 22 Jan 2025ATAI LIFE SCIENCE…atai Life Sciences market capitalization at or above US$10 billion · stated 31 Jul 2024atai Life Sciences market capitalization at or above US$10 billion · restated 31 Jul 2024 · p 90%atai Life Sciences market capitalization at or above US$10 billion · void 31 Jul 2026ATAI SHARE PRICE…atai share price at or above twice its 16 May 2025 close · stated 16 May 2025atai share price at or above twice its 16 May 2025 close · restated 16 May 2025 · p 70%MENTAL HEALTH BEC…Mental health becomes the largest therapeutic-area market in healthcare · stated 5 Jun 2025Mental health becomes the largest therapeutic-area market in healthcare · restated 5 Jun 2025 · p 90%BPL-003 ANNUAL SA…BPL-003 annual sales at or above US$1 billion · stated 1 Jul 2025BPL-003 annual sales at or above US$1 billion · restated 1 Jul 2025 · p 50%A LARGE PHARMACEU…A large pharmaceutical company partners with atai on a psychedelic program · stated 1 Oct 2025A large pharmaceutical company partners with atai on a psychedelic program · restated 1 Oct 2025 · p 70%ATAI LIFE SCIENCE…atai Life Sciences market capitalization at or above US$10 billion · stated 24 Oct 2025atai Life Sciences market capitalization at or above US$10 billion · restated 24 Oct 2025 · p 50%ATAI LIFE SCIENCE…atai Life Sciences market capitalization at or above US$20 billion · stated 24 Oct 2025atai Life Sciences market capitalization at or above US$20 billion · restated 24 Oct 2025 · p 70%ATAI LIFE SCIENCE…atai Life Sciences market capitalization at or above US$50 billion · stated 24 Oct 2025atai Life Sciences market capitalization at or above US$50 billion · restated 24 Oct 2025 · p 70%THREE OR MORE AT-…Three or more at-home depression treatment devices on the US market · stated 1 Jan 2026Three or more at-home depression treatment devices on the US market · restated 1 Jan 2026 · p 90%AT LEAST TWO PAND…At least two pandemic-era mental-health companies cease operations · stated 1 Jan 2026At least two pandemic-era mental-health companies cease operations · restated 1 Jan 2026 · p 90%ATAIBECKLEY (ATAI…AtaiBeckley (ATAI) added to a major stock index · stated 18 Feb 2026AtaiBeckley (ATAI) added to a major stock index · restated 18 Feb 2026 · p 70%ATAIBECKLEY (ATAI…AtaiBeckley (ATAI) added to a major stock index · stated 7 May 2026AtaiBeckley (ATAI) added to a major stock index · restated 7 May 2026 · p 70%AtaiBeckley (ATAI) added to a major stock index · restated 7 May 2026 · p 80%AtaiBeckley (ATAI) added to a major stock index · hit 22 May 2026TODAY2023202520272029203120332035

Headline panel · Company and market outcomes

Claims

16 claims since 2022; 4 resolved, 11 pending.

truefalsependingvoid
20232024202520262027202820292030203120322033203420358 SEP 2022SAINT neuromodulation system becomes commercially available in the US · true · p 90%16 NOV 2022atai Life Sciences market capitalization at or above US$10 billion · pending · p 50%AFF12 MAR 2023BetterHelp or Teladoc Health ceases operations · false · p 50%24 JUN 2024Spravato annual sales at or above US$1 billion · true · p 70%31 JUL 2024atai Life Sciences market capitalization at or above US$10 billion · void · p 90%AFF16 MAY 2025atai share price at or above twice its 16 May 2025 close · pending · p 70%AFF5 JUN 2025Mental health becomes the largest therapeutic-area market in healthcare · pending · p 90%1 JUL 2025BPL-003 annual sales at or above US$1 billion · pending · p 50%AFF1 OCT 2025A large pharmaceutical company partners with atai on a psychedelic program · pending · p 70%AFF24 OCT 2025atai Life Sciences market capitalization at or above US$10 billion · pending · p 50%AFF24 OCT 2025atai Life Sciences market capitalization at or above US$20 billion · pending · p 70%AFF24 OCT 2025atai Life Sciences market capitalization at or above US$50 billion · pending · p 70%AFF1 JAN 2026Three or more at-home depression treatment devices on the US market · pending · p 90%AFF1 JAN 2026At least two pandemic-era mental-health companies cease operations · pending · p 90%18 FEB 2026AtaiBeckley (ATAI) added to a major stock index · pending · p 70%AFF7 MAY 2026AtaiBeckley (ATAI) added to a major stock index · true · p 80%AFFTODAYDOT AREA = P · HAIRLINE = SAID TO DUE

Company and market outcomes · all admitted items